

Late-Stage Chronic Kidney Disease Drugs Market Poised for Rapid Growth, Expected to Reach \$10.94 Billion by 2028

The Business Research Company's Late-Stage Chronic Kidney Disease Drugs Global Market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033

LONDON, GREATER LONDON, UK, July 4, 2024 /EINPresswire.com/ -- The <u>late-</u> <u>stage chronic kidney disease drugs</u> <u>market</u> has experienced significant growth in recent years, driven by advancements in diagnostic



capabilities and an aging population. From \$6.38 billion in 2023, the market is projected to grow to \$7.16 billion in 2024, at a compound annual growth rate (CAGR) of 12.2%. This growth can be attributed to the increasing prevalence of diabetes and hypertension, alongside greater awareness of kidney diseases and expansions in pharmaceutical research and development

"

You Can Now Pre Order Your Report To Get A Swift Deliver With All Your Needs "

> The Business Research Company

efforts.

Rising Healthcare Expenditure and Technological Advancements Fuel Market Expansion The late-stage chronic kidney disease drugs market is expected to see continued robust growth, reaching \$10.94 billion by 2028, with a CAGR of 11.2%. Factors contributing to this forecasted growth include rising healthcare expenditure, adoption of precision medicine approaches,

and global initiatives aimed at kidney disease awareness. Key trends in the coming years include the expansion of regenerative medicine therapies, the rise of telemedicine for CKD management, and the development of combination therapies and early intervention strategies.

Explore the global late-stage chronic kidney disease drugs market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=12196&type=smp

Key Players and Strategic Collaborations

Major companies such as Pfizer Inc., Johnson & Johnson, and AbbVie Inc. are pivotal in driving innovation within the market. Strategic collaborations, like the partnership between Evotec SE and Chinook Therapeutics to develop precision medicines, underscore the industry's focus on advancing treatments for chronic kidney diseases.

Emphasis on Precision Medicine and Innovative Therapies

Companies are increasingly focusing on precision medicine and innovative therapies to address the diverse needs of chronic kidney disease patients. For example, initiatives aimed at discovering novel mechanisms and developing precision therapies are leveraging comprehensive molecular datasets to enhance treatment efficacy.

Market Segments

• Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders

• Indication Type: Late Stage Chronic Kidney Disease Induced Hyperparathyroidism, Late Stage Chronic Kidney Disease Induced Hyperphosphatemia, Late Stage Chronic Kidney Disease Induced Hyperkalemia

• Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies

Regional Insights: North America Leading the Market

North America emerged as the largest region in the late-stage chronic kidney disease drugs market in 2023, with robust growth expected to continue. The report provides comprehensive insights into regional dynamics, market trends, and growth opportunities across Asia-Pacific, Western Europe, Eastern Europe, South America, Middle East, and Africa.

Order your report now for swift delivery

https://www.thebusinessresearchcompany.com/report/late-stage-chronic-kidney-disease-drugsglobal-market-report

Late Stage Chronic Kidney Disease Drugs Global Market Report 2024 from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Late Stage Chronic Kidney Disease Drugs Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on late stage chronic kidney disease drugs market size, late stage chronic kidney disease drugs market drivers and trends, late stage chronic kidney disease drugs market major players, competitors' revenues, market positioning, and market growth across geographies. The late stage chronic kidney disease drugs market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company: Anti-Hypertensive Drugs Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/anti-hypertensive-drugs-global-market-report</u>

Acne Drugs Global Market Report 2024 https://www.thebusinessresearchcompany.com/report/acne-drugs-global-market-report

Drugs For Erectile Dysfunction Global Market Report 2024 <u>https://www.thebusinessresearchcompany.com/report/drugs-for-erectile-dysfunction-global-</u> <u>market-report</u>

About The Business Research Company

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information The Business Research Company Europe: +44 207 1930 708 Asia: +91 8897263534 Americas: +1 315 623 0293

Oliver Guirdham The Business Research Company +44 20 7193 0708 info@tbrc.info Visit us on social media: Facebook X LinkedIn This press release can be viewed online at: https://www.einpresswire.com/article/725088548

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2024 Newsmatics Inc. All Right Reserved.